Investor Relations Captor Therapeutics ®
Information on receipt of NCBR's letter of completion for project CT-04
Current Report No. 4/2023
Date of preparation: 2 March 2023
Subject: Information on receipt of NCBR's letter of completion for project CT-04
Legal basis: Article 17(1) of the MAR Regulation - confidential information
The Managemt Board Captor Therapeutics S.A., based in Wrocław (the "Company"), announces that on 2 March 2023. The Company has received a letter from the National Centre for Research and Development ("NCBR") regarding project CT- 04 (design and development of a first-in-class drug candidate, a small-molecule degrader, for the treatment of colorectal cancer) (the "Project"), responding to the Company's letter requesting termination of the funding agreement for project CT-04 (which the Company reported on 31 October 2022 in current report No. 38/2022).
NCBiR analysed the final information submitted by the Company and concluded that further implementation of the project would not lead to the achievement of its objective within the assumed timeframe. According to NCBR's external expert, the cessation of further work is objectively justified. The Company, in NCBR's view, had made every effort to carry out the Project to the date of cessation in accordance with the scope of the contract. In accordance with the contract, NCBR considered the Project to be completed. The amount of funding the Company will receive will be calculated by NCBR on the basis of the eligible costs approved by NCBR.
The content of the NCRD's letter is in line with the application and the Company's expectations in the above regard and confirms that there is no need to return the funds received and used so far.